United States - English - NLM (National Library of Medicine)

westminster pharmaceuticals, llc - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl), citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate and citric acid oral solution usp is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated. in addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. it is also effective in correcting the acidosis of certain renal tubular disorders where the administration of potassium citrate may be preferable. this product is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary ph around the clock, usually without the necessity of a 2 a.m. dose. this product alkalinizes the urine without producing a systemic alkalosis in recommended dosage. it is highly palatable, pleasant tasting and tolerable, even when administered for l

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate is indicated for the management of renal tubular acidosis [see clinical studies (14.1)]. potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see clinical studies (14.2)]. potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones [see clinical studies (14.3)]. potassium citrate extended-release tablets are contraindicated: - in patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). - in patients in whom there is cause for arrest or delay in tablet passage through the gastroi

United States - English - NLM (National Library of Medicine)

chartwell rx, llc - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl), citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate and citric acid oral solution is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated. in addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. it is also effective in correcting the acidosis of certain renal tubular disorders where the administration of potassium citrate may be preferable. this product is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary ph around the clock, usually without the necessity of a 2 a.m. dose. this product alkalinizes the urine without producing a systemic alkalosis in recommended dosage. it is highly palatable, pleasant tasting and tolerable, even when administered for long

United States - English - NLM (National Library of Medicine)

cypress pharmaceutical, inc. - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl), citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 3.3 g - cytra-k crystals is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated. in addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. it is also effective in correcting the acidosis of certain renal tubular disorders where the administration of potassium citrate may be preferable. cytra-k crystals is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary ph around the clock, usually without the necessity of a 2 a.m. dose. cytra-k crystals alkalinizes the urine without producing a systemic alkalosis in recommended dosage. it is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. potassium cit

United States - English - NLM (National Library of Medicine)

pai holdings, llc - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl), sodium citrate (unii: 1q73q2julr) (anhydrous citric acid - unii:xf417d3psl), citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 550 mg in 5 ml - tricitrates sf oral solution is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract. in addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. it is also effective in correcting the acidosis of certain renal tubular disorders. this product is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urine ph around the clock, usually without the necessity of a 2 a.m. dose. this product alkalinizes the urine without producing a systemic alkalosis in recommended dosage. it is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. potassium citrate and sodium citrate do not neutralize the gastric juice or disturb digestion. severe renal impairment with oliguria o

United States - English - NLM (National Library of Medicine)

bluebay shandong co.,ltd - potassium citrate (unii: ee90oni6ff) (potassium citrate - unii:ee90oni6ff) -

United States - English - NLM (National Library of Medicine)

wuhan longke biotechnology co., ltd. - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl) -

Philippines - English - FDA (Food And Drug Administration)

d.b. manix int'l inc - potassium citrate (as monohydrate) - tablet, extended release - 1.080g (10meq)

Philippines - English - FDA (Food And Drug Administration)

euro-health care phils inc - potassium citrate (as monohydrate) - tablet, extended release - 1.080g (10meq)

New Zealand - English - Medsafe (Medicines Safety Authority)

colgate-palmolive limited (nz) - potassium nitrate 5%{relative}; sodium monofluorophosphate 0.755%{relative};  ;  ;  ; potassium citrate monohydrate 5.53%{relative};  ; sodium monofluorophosphate 0.755%{relative}; potassium citrate monohydrate 5.53%{relative}; sodium monofluorophosphate 0.76%{relative} - toothpaste - active: potassium nitrate 5%{relative} sodium monofluorophosphate 0.755%{relative}       excipient: carmellose sodium glycerol dental type silica (zeodent 105-abrasive) dental type silica (hisil dt267 synth. amorphous ppt silica) macrogol 600 purified water saccharin sodium silica, amorphous, fumed, cryst. free sodium laurilsulfate sorbitol spearmint flavour k91-4479 titanium dioxide active: potassium citrate monohydrate 5.53%{relative}   sodium monofluorophosphate 0.755%{relative} excipient: brilliant blue fcf carmellose sodium glycerol spearmint flavour gereen (k91-5943) dental type silica (sorbosil ac43 synth amorphous ppt silica) dental type silica (hisil dt267 synth. amorphous ppt silica) macrogol 600 methoxyethylene-maleic anhydride copolymer purified water saccharin sodium silica, amorphous, fumed, cryst. free sodium hydroxide sodium laurilsulfate sodium pyrophosphate sorbitol titanium dioxide xanthan gum active: potassium citrate monohydrate 5.53%{relative} sodium monofluorophosphate 0.76%{relative} excipient: brilliant blue fcf carmellose sodium glycerol spearmint flavour gereen (k91-5943) dental type silica (sorbosil ac43 synth amorphous ppt silica) dental type silica (hisil dt267 synth. amorphous ppt silica) macrogol 600 methoxyethylene-maleic anhydride copolymer purified water saccharin sodium silica, amorphous, fumed, cryst. free sodium hydroxide sodium laurilsulfate sodium pyrophosphate sorbitol titanium dioxide xanthan gum